SYNTHESIS, ANTIMICROBIAL, ANTITUBERCULAR AND CHEMINFORMATIC STUDIES OF 2-(1-BENZOFURAN-2-YL)-N'-[(3Z)-2-OXO-1, 2-DIHYDRO-3H-INDOL-3-YLIDENE] QUINOLINE-4-CARBOHYDRAZIDE AND ITS DERIVATIVES
DOI:
https://doi.org/10.22159/ijpps.2017v9i5.17564Keywords:
Benzofuran, Quinoline, Isatin, Antimicrobial, Antitubercular, ADMET and MABA methodAbstract
Objective: Synthesis of novel 2-(1-benzofuran-2-yl)-N'-[(3Z)-2-oxo-1, 2-dihydro-3H-indol-3-ylidene] quinoline-4-carbohydrazide and its derivatives for antimicrobial and antitubercular activity.
Methods: Synthesis was carried out using the general method and the structures were confirmed by IR, 1H-NMR, [13]C-NMR and mass spectral analysis. The antibacterial activity was carried by agar well diffusion method, antifungal activity was performed by poison food technique and antitubercular activity was carried out by Microplate Alamar Blue Assay (MABA) method with the help of H37Rv. In silico absorption, distribution, metabolism, excretion, toxicity (ADMET) study of the drug, likeliness was carried out in ACD/lab-2.
Results: The results revealed that at 25 mg/ml concentration, compounds 3a and 5a showed good antibacterial activity at 3.5±0.1, 3.8±0.3, 3.6±0.2 respectively against E. coli, K. pneumonia and S. typhimurium, when compared with drug streptomycin with similar concentration. The percentage of inhibition found at 50 µg/ml concentration, compounds 2b and 6a exhibited good antifungal activity at 53±1.15, 57±1.52 against A. flavus and C. neoformans, compared with standard drug fluconazole. The increase in activity was found to be dose dependent. The analogue 2a showed good antitubercular activity at 12.5±0.5 µg/ml, compounds 2b, 3a, 4a-b, 5a-b and 6a-b exhibited significant activity at 25±0.57 µg/ml and compound 3b showed moderate activity at 50±0.57 µg/ml. The mean value of P<0.05 were considered to be statistically significant. The absorption, distribution, metabolism, excretion and toxicity studies of the entitled molecules were analyzed and found to be in acceptable range.
Conclusion: The study reveals that compounds containing benzofuran coupled nitrogen heterocycles are essential for activity as they possess excellent drug-like characteristics, suggesting to be potentially best inhibitor of H37Rv strain. The in silico ADME analysis also revealed that all the compounds were in acceptable range to obey the pharmacokinetic parameters.
Downloads
References
Global tuberculosis control: surveillance, financing and planning. World Health Organization; 2015.
Blumberg HM, Burman WG, Chaisson RE, Daley CL, Etkind SC, Friedman LN, et al. American thoracic society/centers for disease control and prevention/infectious diseases society of America: treatment of tuberculosis. Am J Respir Crit Care Med 2003:167;603-62.
Goletti D, Weissman D, Jackson RW, Graham NM, Vlahov D, Klein RS, et al. Effect of Mycobacterium tuberculosis on HIV replication. Role of immune activation. J lmmunol 1996:157;1271-8.
Spigelman MK. New tuberculosis therapeutics: a growing pipeline. J Infect Dis 2007:196;S28-S34.
Mdluli K, Spigelman M. Novel targets for tuberculosis drug discovery. Curr Opin Pharmacol 2006:6;459-67.
Spigelman M, Gillespie S. Tuberculosis drug development pipeline: progress and hope. Lancet 2006:367;945-7.
Ginsberg AM, Spigelman M. Challenges in tuberculosis drug research and development. Nat Med 2007:13;290-4.
Duncan K. Progress in TB drug development and what is still needed. Tuberculosis (Edinb) 2003:83;201-7.
Duncan K. Identification and validation of novel drug targets in tuberculosis. Curr Pharm Des 2004:10;3185-9.
Komeilizadeh H. Does nature prefer heterocycles? Iranian J Pharm Res 2006:4;229-30.
Abdel-Wahab BF, Abdel-Aziz HA, Ahmed EM. Synthesis and antimicrobial evaluation of 1-(benzofuran-2-yl)-4-nitro-3-arylbutan-1-ones and 3-(benzofuran-2-yl)-4, 5-dihydro-5-aryl-1-[4-(aryl)-1,3-thiazol-2-yl]-1H-pyrazoles. Eur J Med Chem 2009:44;2632-5.
Koca M, Servi S, Kirilmis C, Ahmedzade M, Kazaz C, Özbek B, et al. Synthesis and antimicrobial activity of some novel derivatives of benzofuran: part 1. Synthesis and antimicrobial activity of (benzofuran-2-yl) (3-phenyl-3-methylcyclobutyl) ketoxime derivatives. Eur J Med Chem 2005:40;1351-8.
Chauhan PMS, Srivastava SK. Present trends and future strategy in chemotherapy of malaria. J Med Chem 2001:8;1535-42.
Sanjay SP, Shapi AS, Thomas D, Rajgopal JL, Kumar VS. Ionic liquid-promoted regiospecific friedlander annulation: a novel synthesis of quinolines and fused polycyclic quinolines. J Org Chem 2003:68;9371-8.
Lau KY, Mayr A, Cheung KK. Synhesis of transition metal isocyanide complexes containing hydrogen bonding sites in a peripheral location. Inorg Chim Acta 1999:285;223-32.
Raman N, Muthuraj V, Ravichandran S, Kulandaisamy A. Synthesis, characterisation and electrochemical behaviour of Cu(II), Co(II), Ni(II) and Zn(II) complexes derived from acetylacetone and p-anisidine and their antimicrobial activity. J Chem Sci 2003:115;161-7.
Sridhar SK, Ramesh A. Synthesis, characterization and pharmacological screening of some isatinoid compounds. J Indian Chem Soc 2002:41B;668-72.
Piotr P, Bogumil B. Spectroscopic studies and PM3 semiempirical calculations of schiff bases of gossypol with L-amino acid methyl esters. Biopolymers 2002:67;61-9.
Sari N, Arslan S, Logoglu E, Sakiyan I. Antibacterial activities of some new amino acid-schiff bases. G U J Sci 2003:16;283-8.
Holla BS, Rao BS, Shridhara K, Akberali PM. Studies on arylfuran derivatives. Part XI. Synthesis, characterisation and biological studies on some mannich bases carrying 2, 4-dichlorophenylfurfural moiety. Farmaco 2000:55;338-44.
Capdeville R, Buchdunger E, Zimmermann J, Matter A. Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug. Nat Rev Drug Discovery 2002:1;493-502.
Anantacharya R, Manjulatha K, Satyanarayan ND, Santoshkumar S, Kaviraj MY. Antiproliferative, DNA cleavage, and ADMET study of substituted 2-(1-benzofuran 2 yl) quinoline-4-carboxylic acid and its esters. Cogent Chem 2016:2;1158382. https://doi.org/10.1080/23312009.2016. 1158382
Manjunatha KS, Manjulatha K, Satyanarayan ND, Kaviraj MY, Adarsha HJ. Anti-proliferative and ADMET screening of novel 3-(1H-indol-3-yl) 1, 3-diphenylpropan1-one derivatives. Cogent Chem 2016:2;1172542. http://dx.doi.org/10.1080/23312009. 2016.1172542
Satyanarayan ND, Santoshkumar S, Sheelavanth S, Yadav DB, Anantacharya R, Sandeep T. Antitubercular, antibacterial and molecular docking studies of new 2 (naphtha [2, 1-] furan-2-yl) quinoline-4-carboxylic acids and their esters. Inventi Impact: Med Chem 2016;3:75-83.
Lutz W. The application of multi-component reactions in drug discovery. Curr Med Chem 2002:9;1241-53.
Santoshkumar S, Manjulatha K, Satyanarayan ND, Anantacharya R, Harishkuar S, Harishkuar HN, et al. Antiproliferative, ADMET and potential in silico g6pdh inhibitory activity of novel 2-(1-benzofuran-2-yl)-4-(5-phenyl-4h-1, 2, 4-triazol-3-yl) quinoline derivatives. Int J Pharm Pharm Sci 2016:8;313-9.
Saundane AR, Rudresh K, Satyanarayan ND, Hiremath SP. Pharmacological screening of 6H, 11H-indol [3,2-c] isoquinolin-5-ones and their derivatives. Indian J Pharm Sci 1998:60;379-83.
Pathak PD, Sharma KD. Determination of the antifungal activity of some organic chemicals. Def Sci J 1984:34;311-6.
Maria CSL, Marcus VN de Souza, Alessandra CP, Marcelle de LF, Raoni SBG, Thais Cristina MN, et al. Evaluation of the antitubercular activity of nicotinic and isoniazid analogues. ARKIVOC 2007:15;181-91.
Feixiong C, Weihua L, Yadi Z, Jie S, Zengrui W, Guixia L, et al. Classification of cytochrome p450 inhibitors and non-inhibitors using combined classifiers. J Chem Inf Model 2012:52;3099-105.
Lin JH, Yamazaki M. Role of P-glycoprotein in pharmacokinetics: clinical implications. Clin Pharmacokinet 2003:42;59-98.
Segura A, Duque E, Mosqueda G, Ramos JL, Junker F. Multiple responses of gram-negative bacteria to organic solvents. Environ Microbiol 1999:1;191-8.
Eswaran S, Adhikar AV, Chowdhury IH, Pal NK, Thomas KD. New quinoline derivatives: synthesis and investigation of antibacterial and antituberculosis properties. Eur J Med Chem 2010:45;3374-83.
Krieger IV, Freundlich JS, Gawandi VB, Roberts JP, Gawandi VB, Sun Q, et al., the Structure-guided discovery of phenyl-diketo acids as potent inhibitors of M. tuberculosis malate synthase. Chem Biol 2012:19;1556-67.
Fu G, Wu J, Liu W, Zhu D, Hu Y, Deng J, et al. Crystal structure of DNA gyrase B' domain sheds lights on the mechanism for T-segment navigation. Nucleic Acids Res 2009:37;5908-16.
Gulten G, Sacchettini JC. Structure of the Mtb CarD/RNAP beta-lobes complex reveals the molecular basis of interaction and presents a distinct dna-binding domain for mtb card. Structure 2013:21;1859-69.
Sandy J, Holton S, Fullham E, Sim E, Noble MEM. Binding of the antitubercular drug isoniazid to the arylamine n-acetyltransferase protein from mycobacterium smegmatis. Protein Sci 2005:14;775-82.
Published
How to Cite
Issue
Section
